Article
Immunomedics' deal mastermind in line for $2.35B payout after Gilead buy—despite the lack of a bi
Rating:
0.0
Views:
78
Likes:
1
Library:
1
Behzad Aghazadeh, the Immunomedics executive chairman who previously worked hard as an activist investor to derail a $2 billion licensing deal with Seattle Genetics, is now on tap for a whopping $2.35 billion from selling the roughly 11% stake he has in Immunomedics shares to Gilead. Contrary to what industry watchers assumed, the Big Biotech didn't fight through a bidding war to land the $21 billion deal.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value